Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The development of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) leads to significant morbidity and mortality.1 ILD impacts approximately 10% of patients with RA and even higher percentages have subclinical ILD.2 3 Despite the clinical impact of ILD in a patient with RA, this comorbidity is poorly understood.
Recently, we and others have leveraged our understanding of idiopathic pulmonary fibrosis (IPF) to better understand RA-ILD given similarities in demographics, radiology, pathology, natural history and more recently genetics.4 Looking to large, unbiased ’omic-based analyses, including proteomics, to further our understanding of RA-ILD is a logical next step. These approaches could identify novel and shared biomarkers …
Contributors SM and JSL contributed equally to this editorial.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Commissioned; externally peer reviewed.